MapLight Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher A. Kroeger
- Full Time Employees
- 133
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 800 Chesapeake Drive Redwood City CA United States of America 94063
- IPO Date
- Oct 24, 2025
- CIK
- 0001770069
- Website
- maplightrx.com
- Similar Companies
- Business
- MapLight Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the discovery, development, and delivery of circuit-specific therapeutics for central nervous system (CNS) disorders. The company focuses on developing innovative treatments for brain disorders including schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, and Parkinson’s disease. Its core products and pipeline candidates include novel muscarinic receptor agonists such as ML-007C-MA, which is an oral M1/M4 muscarinic receptor modulator currently in Phase 2 clinical trials for schizophrenia and Alzheimer’s disease psychosis. The company’s technology platform leverages proprietary innovations including optogenetics, STARmap spatial transcriptomics, and neural circuit pharmacology to identify and target specific brain circuits implicated in complex neuropsychiatric and neurological diseases. Founded in 2018 and headquartered in the San Francisco Bay Area, MapLight operates primarily in the United States with collaborations across leading academic research institutions. Recently, MapLight completed a significant $372.5 million Series D financing round in mid-2025 led by Forbion and Goldman Sachs, with participation from prominent investors including Sanofi, T. Rowe Price, and Novo Holdings, to advance its CNS therapeutic pipeline. The company also initiated Phase 2 clinical studies for its novel ML-007C-MA compound targeting schizophrenia and Alzheimer’s disease psychosis, positioning it competitively in the CNS market alongside peers such as Bristol Myers Squibb. This financing and clinical advancement reflect strategic growth and a commitment to expanding its product portfolio in neuroscience therapeutics. MapLight’s differentiated approach aims to improve treatment efficacy and tolerability for patients with brain disorders by precisely modulating dysfunctional neural circuits, addressing a critical unmet need in psychiatry and neurology. MapLight’s product offerings extend to multiple clinical candidates in various stages of development, with a focus on therapies that treat symptoms of autism spectrum disorder, Parkinson’s disease, hyperactivity, and impulsivity. Its pipeline includes ML-004, ML-021, and ML-009 among others, targeted for treatment across a broad spectrum of brain disorders. The company also has strategic partnerships and investor backing from leading life sciences and pharmaceutical entities, supporting its rapid development and clinical trial progress. This comprehensive focus on CNS disorders, combined with recent capital infusion and clinical progress, situates MapLight Therapeutics as a notable player in innovative neuropharmaceuticals, advancing therapies that aim to redefine the standard of care for brain disorders.
Company News
BlackRock Inc. Takes $36.74 Million Position in Maplight Therapeutics, Inc. $MPLT
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
MapLight Therapeutics Announces $150 Million Private Placement Financing
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
Maplight Therapeutics (NASDAQ:MPLT) Trading 18.2% Higher on Insider Buying Activity
ADAR1 Capital Management LLC Purchases New Position in Maplight Therapeutics, Inc. $MPLT
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia Transcript
Maplight Therapeutics' Schizophrenia Drug Hits Phase II Primary Endpoint
MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
MapLight's schizophrenia drug fails once-daily test, shares plunge
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
MapLight Therapeutics Announces Changes to Board of Directors
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Phase II IRIS Study Results for ML-004 in Autism Spectrum Disorder Transcript
MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
MapLight Therapeutics to Participate in Upcoming Investor Conferences
This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April